Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2
K Reich, KB Gordon, BE Strober, AW Armstrong, M Miller, YK Shen, Y You, C Han, YW Yang, P Foley, CEM Griffiths
BRITISH JOURNAL OF DERMATOLOGY | WILEY | Published : 2021
BACKGROUND: Psoriasis is a chronic disease requiring long-term therapy. OBJECTIVES: Physician- and patient-reported outcomes were evaluated through week 252 in VOYAGE 1 and VOYAGE 2. METHODS: In total, 1829 patients were randomized at baseline to receive guselkumab 100 mg every 8 weeks, placebo or adalimumab. Patients receiving placebo crossed over to guselkumab at week 16. Patients receiving adalimumab crossed over to guselkumab at week 52 in VOYAGE 1, and randomized withdrawal and retreatment occurred at weeks 28-76 in VOYAGE 2; all patients then received open-label guselkumab through week 252. Efficacy and health-related quality of life (HRQoL) endpoints were analysed through week 252. Sa..View full abstract
The authors wish to thank Cynthia Arnold, BSc, ISMPP CMPP, of Janssen Scientific Affairs, LLC, Horsham, PA for her editorial assistance and writing support for this manuscript. C.E.M.G. is supported in part by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre and is an NIHR Emeritus Senior Investigator. Open Access funding enabled and organized by Projekt DEAL.